Hualan Biological Bacterin Inc.
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetic engineering biological products in China. The company offers influenza vaccine (split virion), recombinant hepatitis B vaccine (hansenula polymorpha), meningococcal polysaccharide vaccine, influenza vaccine (split virion) quadrivalent, and meningococcal polysaccharide vaccine. It a… Read more
Market Cap & Net Worth: Hualan Biological Bacterin Inc. (301207)
Hualan Biological Bacterin Inc. (SHE:301207) has a market capitalization of $1.61 Billion (CN¥11.84 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #14758 globally and #3916 in its home market, demonstrating a 0.05% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hualan Biological Bacterin Inc.'s stock price CN¥19.70 by its total outstanding shares 601027500 (601.03 Million).
Hualan Biological Bacterin Inc. Market Cap History: 2022 to 2026
Hualan Biological Bacterin Inc.'s market capitalization history from 2022 to 2026. Data shows change from $2.34 Billion to $1.61 Billion (-18.23% CAGR).
Hualan Biological Bacterin Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hualan Biological Bacterin Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.27x
Hualan Biological Bacterin Inc.'s market cap is 1.27 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
6.98x
Hualan Biological Bacterin Inc.'s market cap is 6.98 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.34 Billion | $1.83 Billion | $519.63 Million | 1.28x | 4.50x |
| 2023 | $2.20 Billion | $2.41 Billion | $859.97 Million | 0.91x | 2.56x |
| 2024 | $1.43 Billion | $1.13 Billion | $205.52 Million | 1.27x | 6.98x |
Competitor Companies of 301207 by Market Capitalization
Companies near Hualan Biological Bacterin Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Hualan Biological Bacterin Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Hualan Biological Bacterin Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, Hualan Biological Bacterin Inc.'s market cap moved from $2.34 Billion to $ 1.61 Billion, with a yearly change of -18.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.61 Billion | +5.74% |
| 2025 | CN¥1.53 Billion | +6.40% |
| 2024 | CN¥1.43 Billion | -34.95% |
| 2023 | CN¥2.20 Billion | -5.63% |
| 2022 | CN¥2.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Hualan Biological Bacterin Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.61 Billion USD |
| MoneyControl | $1.61 Billion USD |
| MarketWatch | $1.61 Billion USD |
| marketcap.company | $1.61 Billion USD |
| Reuters | $1.61 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.